Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 5 | 2015 | 553 | 0.530 |
Why?
|
| Pulmonary Blastoma | 1 | 2010 | 4 | 0.350 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 61 | 0.340 |
Why?
|
| Adenocarcinoma | 3 | 2018 | 147 | 0.320 |
Why?
|
| Colonic Polyps | 2 | 2018 | 34 | 0.270 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2018 | 42 | 0.270 |
Why?
|
| Esophageal Neoplasms | 2 | 2018 | 54 | 0.260 |
Why?
|
| Adenoma | 2 | 2018 | 60 | 0.260 |
Why?
|
| Colorectal Neoplasms | 2 | 2018 | 113 | 0.240 |
Why?
|
| Biomarkers, Tumor | 3 | 2014 | 202 | 0.200 |
Why?
|
| Hemangioendothelioma | 1 | 2019 | 3 | 0.160 |
Why?
|
| Sirolimus | 1 | 2019 | 20 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2012 | 244 | 0.160 |
Why?
|
| Mucous Membrane | 1 | 2018 | 29 | 0.150 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2016 | 7 | 0.140 |
Why?
|
| Rituximab | 1 | 2016 | 49 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 37 | 0.130 |
Why?
|
| Colon | 1 | 2018 | 142 | 0.130 |
Why?
|
| Stroke Volume | 1 | 2016 | 58 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 40 | 0.130 |
Why?
|
| Middle Aged | 9 | 2018 | 9269 | 0.120 |
Why?
|
| Carcinoma | 1 | 2016 | 69 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 61 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 241 | 0.120 |
Why?
|
| Mesothelioma, Cystic | 1 | 2014 | 2 | 0.120 |
Why?
|
| Peritoneal Neoplasms | 1 | 2014 | 8 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 177 | 0.110 |
Why?
|
| Female | 10 | 2018 | 15730 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 2014 | 109 | 0.110 |
Why?
|
| Kidney | 1 | 2014 | 175 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 13 | 0.100 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2013 | 15 | 0.100 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2013 | 12 | 0.100 |
Why?
|
| Humans | 14 | 2019 | 28436 | 0.100 |
Why?
|
| Immunoassay | 1 | 2012 | 40 | 0.100 |
Why?
|
| Male | 11 | 2019 | 15291 | 0.100 |
Why?
|
| C-Peptide | 1 | 2011 | 6 | 0.100 |
Why?
|
| Necrobiotic Xanthogranuloma | 1 | 2011 | 2 | 0.100 |
Why?
|
| Plasma Cells | 1 | 2011 | 6 | 0.100 |
Why?
|
| Paraproteinemias | 1 | 2011 | 6 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2011 | 10 | 0.100 |
Why?
|
| Mediastinum | 1 | 2011 | 7 | 0.100 |
Why?
|
| Cytokines | 1 | 2013 | 230 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 409 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 206 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 59 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 371 | 0.080 |
Why?
|
| Smoking | 1 | 2010 | 177 | 0.080 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2008 | 15 | 0.080 |
Why?
|
| Aged | 7 | 2018 | 9277 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 1 | 2008 | 66 | 0.080 |
Why?
|
| Meningioma | 1 | 2008 | 12 | 0.070 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 14 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 97 | 0.070 |
Why?
|
| Colonoscopy | 2 | 2018 | 74 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2016 | 3615 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 825 | 0.060 |
Why?
|
| Biopsy | 2 | 2014 | 220 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 492 | 0.050 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 28 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 730 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 4857 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2018 | 20 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 89 | 0.040 |
Why?
|
| Risk Factors | 2 | 2016 | 2408 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 120 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2018 | 3612 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 267 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 105 | 0.030 |
Why?
|
| Adult | 3 | 2014 | 8107 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 137 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 307 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 10 | 0.030 |
Why?
|
| Child | 1 | 2019 | 1420 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 362 | 0.030 |
Why?
|
| Chemokine CCL3 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Granuloma | 1 | 2013 | 15 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 15 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2013 | 20 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 27 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 62 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2013 | 79 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 144 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 52 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 90 | 0.020 |
Why?
|
| Pneumonia | 1 | 2013 | 77 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 192 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 331 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 640 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 377 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 677 | 0.020 |
Why?
|
| Ampulla of Vater | 1 | 2008 | 2 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 717 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2008 | 23 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 17 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 52 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 81 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 596 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 125 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2008 | 139 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 2069 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 1809 | 0.020 |
Why?
|